Business Context and Reporting Period
This Form 8-K is a current report filed by Hemispherx Biopharma, Inc. on September 14, 2017, regarding events occurring on September 13, 2017. The filing details the results of the Company's 2017 Annual Meeting of Stockholders. Note: The input metadata references "AIM Immunotech Inc.", but the filing text explicitly identifies the registrant as Hemispherx Biopharma, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
The requisite quorum of 40.0% was present at the meeting. Stockholders voted on the following matters:
- Election of Directors: All three nominees (Thomas K. Equels, William M. Mitchell, Stewart L. Appelrouth) received significant "For" votes (approx. 2.43M - 2.45M each) but faced substantial "Broker Non-Votes" (13,100,243 each).
- Ratification of Independent Accountants: RSM US LLP was ratified with 14,665,206 votes "For" versus 652,933 "Against".
- Executive Compensation (Say-on-Pay): The advisory vote on Named Executive Officer compensation passed with 2,131,948 "For" votes against 514,484 "Against".
- Frequency of Say-on-Pay Vote: Stockholders voted to hold this advisory vote Every Year (1,769,972 votes), rejecting the "Every Three Years" (752,682 votes) and "Every Two Years" (111,469 votes) options.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the tabulation of votes cast at the annual meeting.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name ("AIM Immunotech Inc.") and the filing registrant ("Hemispherx Biopharma, Inc.").
- Confirm the high volume of "Broker Non-Votes" (13.1M) relative to the "For" votes (approx. 2.4M) in the director elections to understand voting power dynamics.
- Review the Company's subsequent filings to see if the shareholder preference for annual executive compensation votes has been implemented.
- Check for separate financial reports (10-K or 10-Q) as this 8-K contains no financial performance data.